CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.
| Revenue (Most Recent Fiscal Year) | $371.21M |
| Net Income (Most Recent Fiscal Year) | $-153.61M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.92 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.45 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -40.60% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -8.09% |
| Return on Assets (Trailing 12 Months) | -6.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $23.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.94 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.96 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 84.88M |
| Free Float | 81.40M |
| Market Capitalization | $4.92B |
| Average Volume (Last 20 Days) | 1.19M |
| Beta (Past 60 Months) | 1.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |